# A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors

Source: https://onco.cc/trials/nct07198321/  
OnCo record `nct07198321` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in colorectal cancer, run by Genfleet Therapeutics (Shanghai) Inc., not yet recruiting.

## Summary

A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors is a phase 1/2, interventional study registered as NCT07198321 by Genfleet Therapeutics (Shanghai) Inc., with a registry enrolment figure of 450 participants, started 2025-09-22 and due to reach its primary completion in 2027-09-22. Interventions recorded: GFH276. Conditions listed: Cancer; PDAC; CRC (Colorectal Cancer); NSCLC. Primary outcome: Phase Ia:The incidence and severity of AEs and SAEs; Phase Ia:The incidence of DLT events; Phase Ib:The incidence and severity of AEs and SAEs. Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07198321
- Phase: 1/2
- Setting: A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study
- Sponsor: Genfleet Therapeutics (Shanghai) Inc.
- Enrolled: 450

## Sources

- ClinicalTrials.gov NCT07198321: https://clinicaltrials.gov/study/NCT07198321

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- companies: [GenFleet Therapeutics](https://onco.cc/companies/genfleet/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07198321.json